GlyNAC: The Two-Supplement Stack Reversing 8 Aging Hallmarks in Peer-Reviewed Trials.

What GlyNAC is — and why each precursor alone is insufficient

GlyNAC stands for Glycine + NAC (N-acetylcysteine). The combination is not a novel molecule — it is two off-patent amino acids and amino acid derivatives co-administered as precursors to glutathione (GSH), the body's master intracellular antioxidant. The mechanism is direct: glutathione is a tripeptide synthesized from three amino acids — glutamate (glutamic acid), cysteine, and glycine. In a healthy young person, all three are available in adequate supply. In an aging person, that supply fails — but it fails selectively, and that selectivity is the whole point of the GlyNAC approach.

The rate-limiting precursors for GSH synthesis are cysteine and glycine. Glutamate is rarely deficient in the context of a normal diet. Cysteine is conditionally essential — it is derived partly from methionine via the transsulfuration pathway, a pathway that becomes less efficient with age. NAC (N-acetylcysteine) is a stable, orally bioavailable cysteine prodrug: once absorbed, it is deacetylated intracellularly to release free cysteine. It is the standard clinical strategy for cysteine repletion and has been used safely in adults for decades, primarily in acetaminophen overdose and as a mucolytic.^[12]

Glycine, despite being classified as non-essential, is conditionally deficient in older adults. The synthesis of glycine from serine — the primary endogenous route — declines measurably with age. Dietary glycine intake rarely compensates for the shortfall because it is low in most protein sources relative to demand. When both cysteine and glycine are deficient, supplementing only one still leaves the other as the rate-limiting step — the enzymatic machinery for GSH synthesis has both precursors available simultaneously, or it doesn't run efficiently. This is why NAC alone, despite its long clinical history, produces more modest GSH increases than GlyNAC does in older adults. The precursor bottleneck is dual, not singular.^[7]

The research program behind GlyNAC was built primarily at Baylor College of Medicine (BCM) in Houston, led by Rajagopal V. Sekhar. The progression from mechanism to pilot trial to randomized controlled trial to mouse lifespan studies represents one of the more coherent experimental programs in the nutritional gerontology space — a field not known for its experimental rigor.

The glutathione problem in aging

Glutathione is not a single-function antioxidant. Its roles are sufficiently broad that a 50% reduction in intracellular GSH concentrations — which is what the aging literature consistently reports by the mid-60s — constitutes a multi-system failure signal, not a single pathway defect.^[8]

The three categories of GSH function that matter most in the aging context are:

• Direct antioxidant: GSH neutralizes reactive oxygen species (ROS) and lipid hydroperoxides directly, and serves as the substrate for glutathione peroxidase (GPx) enzymes. When GSH declines, ROS accumulate — and chronically elevated ROS drive oxidative modification of proteins, lipids, and nucleic acids, which is the downstream damage underlying multiple aging hallmarks.
• Mitochondrial protectant: Mitochondria generate ~90% of cellular ROS as a byproduct of the electron transport chain (ETC). Mitochondrial GSH (mGSH) — a distinct pool from cytosolic GSH — is the primary defense against this ROS load. When mGSH depletes, ETC complex activity degrades, ATP output falls, and mitophagy (the selective autophagy of damaged mitochondria) becomes impaired. The result is a progressive accumulation of dysfunctional mitochondria, a hallmark of aged tissue — the same mitochondrial bottleneck that urolithin A targets through a separate mitophagy-induction pathway.
• Phase II detoxification cofactor: GSH is conjugated to electrophilic compounds by glutathione S-transferase (GST) enzymes in the liver and other tissues, rendering them water-soluble and excretion-ready. This is not a minor housekeeping function — it is how the body neutralizes environmental toxins, drug metabolites, and endogenous oxidative byproducts. A 50% reduction in GSH capacity is a 50% reduction in detoxification throughput. The liver and skin implications of that throughput reduction are covered in depth in our glutathione deep-dive.

The Sekhar group at BCM published an early characterization of the pattern across multiple studies: aging adults show consistently low red blood cell (RBC) GSH, elevated markers of oxidative stress (OxS), and measurable mitochondrial dysfunction — and that the degree of GSH deficiency correlates with the severity of the other defects. The signal is not incidental. GSH deficiency in aging appears to be upstream of a cascade of dysfunction, not merely co-occurring with it.^[7]

GSH doesn't just mop up free radicals. It is the primary gatekeeper of mitochondrial integrity, detoxification capacity, and genomic stability — all of which degrade together when it falls.

The flagship RCT: Kumar et al. 2023 — 8 hallmarks, 16 weeks

The landmark study is Kumar P et al., published in Journals of Gerontology: Biological Sciences in 2023 (PMID: 35975308).^[1] This was a randomized, double-blind, placebo-controlled trial enrolling 24 older adults (mean age approximately 71 years) and 12 young adult controls. Older participants were randomized to either GlyNAC (n=12) or placebo (n=12) for 16 weeks. The GlyNAC arm received 100 mg/kg body weight per day of glycine and 100 mg/kg body weight per day of NAC — for a 70 kg adult, that is roughly 7 g of each per day.

The study measured eight domains that map directly to the canonical hallmarks of aging as defined by López-Otín et al.:

• Oxidative stress: Measured via plasma TBARS (thiobarbituric acid reactive substances — a lipid peroxidation marker) and F2-isoprostanes. Both were elevated at baseline in older adults vs. young controls; both normalized toward young-control levels after GlyNAC supplementation. Placebo showed no change.
• Mitochondrial function: Assessed via maximal mitochondrial ATP production (MitoATP) in peripheral blood mononuclear cells (PBMCs). GlyNAC-treated older adults showed significant improvement in MitoATP; placebo did not. Mitochondrial ATP output is the same substrate that Zone 2 cardio training develops through a complementary exercise-based route.
• Inflammation: Measured via plasma TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin-6), and hsCRP (high-sensitivity C-reactive protein). All three elevated at baseline in older adults; all three declined significantly in the GlyNAC arm. For context, TNF-α reduction was also the key mechanistic signal in the STAMINA senolytic trial — the same inflammatory marker, a different upstream intervention.
• Genomic damage: Quantified via a comet assay measuring DNA strand breaks in lymphocytes. GlyNAC reduced genomic damage scores; placebo did not.
• Autophagy: Measured via LC3A and LC3B expression (autophagy initiation markers). GlyNAC supplementation increased both markers, signaling restored autophagic flux.
• Insulin resistance: Quantified via HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). GlyNAC-treated participants showed significant reductions in HOMA-IR; placebo participants did not.
• Endothelial function: Assessed via flow-mediated dilation (FMD) of the brachial artery — the clinical gold standard for endothelial function. GlyNAC improved FMD significantly in older adults.
• Physical function: Measured via gait speed and grip strength. Both improved in the GlyNAC arm; neither changed meaningfully in placebo.

In all eight domains, GlyNAC-treated older adults moved statistically and meaningfully toward the young-control reference range. The placebo-treated older adults remained where they started. The between-group differences were consistent and reached statistical significance across all primary outcomes.

The Sekhar group had previously published a 24-week open-label pilot (Kumar et al. 2021, Clin Transl Med, PMID: 33783984) in eight older adults showing the same directional findings — and critically, showing that benefits reversed during a 12-week post-supplementation washout period, confirming that the effect is dependent on ongoing supplementation, not a permanent correction.^[6]

What "reversing aging hallmarks" actually means

The phrase "reversing aging hallmarks" is accurate as a description of what the trial measured — but it requires context to be useful rather than misleading.

What the trial measured and showed: specific biomarkers associated with aging hallmarks moved from age-typical values toward young-control values over 16 weeks. That is real. It is peer-reviewed. It replicated directionally across the pilot and the RCT. The effect sizes were meaningful, not marginal.

What the trial did not show, and cannot show in its design: it did not measure mortality, lifespan, or rates of age-related disease over meaningful time horizons. It did not demonstrate that normalizing these biomarkers translates to reduced incidence of cardiovascular disease, dementia, cancer, or other longevity endpoints. Biomarker normalization is not equivalent to outcome prevention — this is a critical distinction in clinical research, and the GlyNAC literature does not yet have the outcome data to close that gap.

Limitations to state directly: sample size was modest (24 older adults randomized). Trial duration was 16 weeks — long enough to see biological effects, short enough to know nothing about long-term safety at these doses or long-term maintenance of effect. The population was community-dwelling older adults without major age-related disease — the results may not generalize to frailer populations or those with comorbidities. The young-adult comparator group was not randomized, making the comparison observational rather than experimental.

The mouse data adds a different dimension. Kumar, Osahon, and Sekhar (Nutrients, 2022, PMID: 35268089) demonstrated that GlyNAC supplementation in old mice extended lifespan by 24% — a substantial effect size that, if translated to humans, would represent one of the largest nutritional longevity signals in mammalian research.^[5] The honest interpretation: mouse lifespan extension is encouraging and mechanistically coherent, but the species gap is real. Mice are not humans. Longevity interventions have a poor track record of translating lifespan data across that gap. The mouse data strengthens the mechanistic case; it does not substitute for human mortality data.

Biomarker normalization is the signal that the underlying machinery is responding. Whether it translates to disease prevention over decades is the question the 16-week RCT cannot answer — and the field hasn't run that trial yet.

The cognitive signal: the 2024 brain health pilot

In 2024, Sekhar et al. published a pilot clinical trial specifically targeting cognitive function and brain health (Innovation in Aging, PMC: 11689385).^[2] This extended the supplementation period to 24 weeks and added cognitive outcome measures. The study enrolled older adults who demonstrated baseline cognitive decline alongside the glutathione and metabolic defects the earlier studies had characterized.

The findings: GlyNAC supplementation for 24 weeks reversed the measured cognitive deficits, alongside normalizing glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, and endothelial dysfunction. When supplementation stopped for 12 weeks, cognitive performance and the underlying biological defects returned to pre-supplementation levels — a finding that parallels the 2021 pilot withdrawal phase.

A mechanistic hypothesis the BCM group introduced is worth noting: the concept of "brain glucose steal." The proposal is that mitochondrial dysfunction in aging impairs the ability of peripheral tissues — muscle, liver, and others — to oxidize glucose efficiently via mitochondrial pathways, forcing them to rely more heavily on circulating blood glucose. The consequence is reduced glucose availability for the brain, which depends on glucose as its primary fuel. GlyNAC supplementation, by restoring mitochondrial function, corrects the glucose partitioning problem — and the investigators propose this as one mechanism behind the cognitive improvement signal.

This is a mechanistic hypothesis, not an established pathway. It is biologically plausible and consistent with the observed data, but it has not been independently replicated and should not be treated as settled science. The cognitive improvement signal itself is real in the pilot data; the brain glucose steal mechanism is one proposed explanation, not a confirmed one.

Supporting the cognitive direction from animal work: Kumar, Osahon, and Sekhar (Antioxidants, 2023, PMC: 10215265) showed that GlyNAC supplementation in old mice improved brain glutathione (156% increase in total GSH vs. untreated aged controls), reduced brain oxidative stress by 42%, restored mitochondrial electron transport complex expression, and improved cognitive performance by 42% on maze task completion time and 33% on error rate.^[4] Neurotrophic factors — BDNF (brain-derived neurotrophic factor), GDNF (glial-derived neurotrophic factor), and NGF (nerve growth factor) — all increased toward young mouse levels. The brain glutathione restoration signal is mechanistically coherent with the cognitive improvements in both animal and human data.

Why glycine specifically — beyond glutathione synthesis

Glycine's contribution to the GlyNAC stack is often framed as purely structural — it supplies one of the three amino acids needed to make GSH, and that's the end of the story. That framing undersells what glycine does as a physiologically active molecule.

Collagen synthesis. Glycine is the most abundant amino acid in collagen, comprising approximately one-third of total collagen residues. Every third residue in the collagen triple helix is glycine — a structural necessity given the amino acid's small side chain allows the tight helical packing that gives collagen its tensile strength. With glycine deficiency in aging, collagen production is constrained. This manifests not just in skin quality but in tendon integrity, bone matrix, cartilage, and vascular wall structure. The collagen deficit of aging is partly a glycine availability problem.

Sleep quality. Glycine acts as an inhibitory neurotransmitter in the central nervous system (CNS), with high concentrations of glycine receptors in the brainstem and spinal cord. Bannai and Kawai (J Pharmacological Sciences, 2012, PMID: 22293292) demonstrated that oral glycine ingestion lowers core body temperature and improves subjective sleep quality in adults with insomnia tendencies — an effect attributed to glycine's ability to facilitate sleep-onset temperature drops via vasodilation in peripheral tissues.^[9] The doses studied were 3 g taken pre-sleep, directly applicable to GlyNAC supplementation regimens.

Methylation and one-carbon metabolism. Glycine participates in one-carbon metabolism via the glycine cleavage system, donating one-carbon units to the folate cycle. This connects glycine availability to the broader landscape of methylation reactions — DNA methylation, histone methylation, and the synthesis of creatine, phosphatidylcholine, and other methylated metabolites. A review by Razak et al. (Oxid Med Cell Longev, 2017, PMID: 28337245) characterized glycine as essential to both glutathione and creatine synthesis, with implications for metabolic and cardiovascular function that extend well beyond its role as a GSH precursor.^[10] On the creatine side of that equation, the cognitive implications are substantial — see the creatine brain-performance data for what creatine synthesis actually delivers to neurons.

The implication: glycine in GlyNAC is not merely a delivery mechanism for one GSH building block. It is itself a functionally active molecule that happens to be chronically deficient in older adults. The stack addresses two separate deficiencies with two compounds that each have their own direct physiological roles — which partly explains why the combined effect exceeds what would be predicted from GSH replenishment alone.

Glycine isn't a passive carrier. It is the backbone of collagen, an inhibitory CNS neurotransmitter, and a one-carbon donor — all simultaneously depleted in the aging context.

Practical use: dosing, timing, sourcing, who it fits

The dosing used in the BCM trials was weight-based: 100 mg/kg/day of glycine and 100 mg/kg/day of NAC. For a 70 kg adult, that is approximately 7 g glycine and 7 g NAC per day. Some protocols in community use report good results at a lower fixed dose — 3 g glycine + 3 g NAC per day — which is more practical to sustain, though this specific dose has not been tested in a published BCM pilot or RCT; all published trials used weight-based dosing (100 mg/kg/day). The published RCT used the higher weight-based dosing; whether the lower dose produces comparable magnitude effects in humans has not been formally tested in an RCT.

Both compounds are available as plain bulk powders without prescription. Glycine powder is inexpensive, mildly sweet, and mixes easily in water. NAC powder or capsules are widely available; NAC has a sulfurous odor that some find off-putting in bulk form, making capsules a practical alternative. The combination can be taken together — there is no known interaction between them, and the BCM protocols did not separate timing.

Timing is practical rather than mechanistic. The BCM studies divided doses across meals to minimize any gastrointestinal discomfort with large NAC doses. High-dose NAC (particularly above 3 g in a single dose) can cause nausea in some individuals; split dosing across two or three meals addresses this reliably. Glycine has no known gastrointestinal burden at these doses.

Who the stack fits well: The trial population was older adults (65+) with measurable deficits in the targeted biomarkers. The biological case is strongest for this population. Younger adults without measurable GSH deficiency or the associated mitochondrial and inflammatory burden are not the studied population — the effect size in a 30-year-old with healthy GSH levels is unknown and potentially minimal. This is not a stack with evidence in optimized young adults; it is a stack with evidence in a population where the underlying deficiency exists.

Drug interactions to flag: NAC is an antioxidant and may theoretically interact with chemotherapeutic agents that operate via oxidative mechanisms — oncology context requires specific medical review. NAC has mild antiplatelet properties; relevant in the context of blood-thinning medication combinations. Beyond these, the safety profile of both compounds at these doses is well-established from decades of clinical use of each compound individually.

What remains unknown

The GlyNAC evidence base is unusually coherent for a nutritional intervention — a pilot, an RCT, animal lifespan data, and a cognitive signal all pointing in the same direction from a single research group over more than a decade. That coherence is also its primary limitation: almost all of the published human evidence comes from one research group at one institution, the Sekhar laboratory at BCM. Independent replication in a different center with a different patient population has not yet been published.

The critical unknowns, stated directly:

• No mortality data. No human trial has been long enough, or powered for the right endpoint, to determine whether GlyNAC supplementation reduces all-cause mortality or extends healthy lifespan in humans. The 24% lifespan extension in mice is a hypothesis-generating finding, not a human result.
• No long-term trial beyond 24 weeks in humans. The longest human supplementation trial in the GlyNAC literature is 24 weeks. Long-term safety and sustained efficacy beyond that window are untested in a controlled setting. The biologically plausible concern with prolonged high-dose antioxidant supplementation — that it might blunt beneficial adaptive ROS signaling — has not been evaluated in this specific context. This same long-term unknown applies to the broader category of mitochondrial-support supplements; the NMN vs NR head-to-head data shows how differently two mechanistically similar compounds can perform once multi-year human trials arrive.
• GSH as a marker, not necessarily the mechanism. GSH normalization is the proposed mechanism, but the question of whether GSH restoration is the cause of the improvements or a correlated marker alongside the actual causal factor remains open. GlyNAC also supplies glycine directly — and glycine has its own downstream effects on collagen, methylation, and sleep that may contribute to observed benefits independently of GSH.
• Population specificity. All human RCT data is in community-dwelling older adults without major active disease. Generalizability to frailer elderly populations, adults with significant metabolic disease, or those on multiple medications is not established.
• Optimal dose in humans. The weight-based RCT dose (100 mg/kg each) has not been formally compared to lower doses in humans. The dose-response curve is unknown.

The honest framing of where GlyNAC sits in 2026: it is the most evidence-supported approach to addressing the dual-precursor deficiency hypothesis of aging-related GSH decline. The biological mechanism is sound, the human trial data is real and consistent, and the safety profile of both compounds is well-characterized from prior clinical use. What it is not — yet — is a proven longevity intervention with mortality or long-term disease-prevention data. That trial hasn't been run.